COMPARATIVE EFFECTS OF DRY NEEDLING AND NEURAL MOBILIZATION ON PAIN, STRENGTH AND RANGE OF MOTION IN PATIENTS WITH GOLFER'S ELBOW (DN-NM-GE)

June 8, 2026 updated by: Abeela Ashraf, Green International University
This randomized clinical trial aims to compare the effectiveness of Dry Needling and Neural Mobilization in patients diagnosed with Golfer's Elbow (Medial Epicondylitis). The study will evaluate the effects of both interventions on pain intensity, grip strength, and range of motion. Participants will be randomly allocated to either the Dry Needling group or the Neural Mobilization group and treated over a specified intervention period. Outcome measures will be assessed at baseline and after treatment to determine which intervention provides greater improvement in pain reduction, muscle strength, and functional mobility. The results may contribute to evidence-based rehabilitation strategies for managing Golfer's Elbow

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Golfer's Elbow (Medial Epicondylitis) is a common musculoskeletal disorder characterized by pain and tenderness over the medial epicondyle of the elbow, often associated with repetitive wrist flexion and forearm pronation activities. The condition can lead to decreased grip strength, restricted range of motion, and impaired functional performance, affecting daily activities and quality of life.

Various physiotherapy interventions have been used for the management of Golfer's Elbow, including Dry Needling and Neural Mobilization. Dry Needling is a technique that targets myofascial trigger points to reduce pain, improve blood flow, and restore muscle function. Neural Mobilization aims to restore the normal mobility and physiological function of peripheral nerves by reducing neural tension and improving neural mechanics.

The purpose of this randomized clinical trial is to compare the effectiveness of Dry Needling and Neural Mobilization in reducing pain, improving grip strength, and increasing range of motion in patients with Golfer's Elbow. Eligible participants will be randomly assigned to one of two intervention groups. Baseline assessments will be conducted before treatment, followed by post-intervention assessments after completion of the treatment protocol.

Primary outcome measures will include pain intensity, assessed using a validated pain scale, while secondary outcomes will include grip strength and elbow/wrist range of motion. Data collected will be analyzed to determine whether one intervention demonstrates superior clinical outcomes compared to the other.

The findings of this study are expected to provide evidence regarding the comparative effectiveness of these commonly used physiotherapy interventions and may assist clinicians in selecting appropriate treatment strategies for patients with Golfer's Elbow.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
29

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab Province
      • Lahore, Punjab Province, Pakistan, 54000
        • Green International University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • • Both male and female patients were included.

    • Diagnosis of Medial Epicondylitis by spiral test clinically confirmed by orthopaedic.

pain is limited on medial epicondyle

  • Pain reproduced with resisted wrist flexion and/or forearm pronation.
  • Aged between 18-40 years
  • Acute to Subacute stage (≥ 6 weeks and ≤ 12 months
  • NPRS score ≥ 4/10 at baseline

Exclusion Criteria:

  • • History of Other elbow pathologies e.g (Lateral epicondylitis , Olecranon bursitis ,Ligament injuries)

    • Radial or ulnar neuropathies not associated with medial epicondylitis.
    • Systemic or inflammatory conditions affecting tendons, such as rheumatoid arthritis
    • Diabetes with neuropathy (unless controlled and neuropathy absent)
    • Previous surgical procedures around the elbow or wrist within the past 6 months
    • Corticosteroid injection, PRP or shockwave therapy within the last 3 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Dry needling
Participants will receive dry needling combined with conventional physiotherapy twice weekly for 6 weeks
Procedure: Dry needling
Participants will receive dry needling to the affected forearm muscles along with conventional physiotherapy. Treatment will be administered twice weekly for 6 weeks, totaling 12 sessions. Outcomes will include pain, grip strength, and range of motion
Procedure: Neural mobilization
Participants will receive neural mobilization techniques along with conventional physiotherapy. Treatment will be administered twice weekly for 6 weeks, totaling 12 sessions. Outcomes will include pain, grip strength, and range of motion.
Experimental: Neural mobilization
Participants will receive neural mobilization combined with conventional physiotherapy twice weekly for 6 weeks
Procedure: Dry needling
Participants will receive dry needling to the affected forearm muscles along with conventional physiotherapy. Treatment will be administered twice weekly for 6 weeks, totaling 12 sessions. Outcomes will include pain, grip strength, and range of motion
Procedure: Neural mobilization
Participants will receive neural mobilization techniques along with conventional physiotherapy. Treatment will be administered twice weekly for 6 weeks, totaling 12 sessions. Outcomes will include pain, grip strength, and range of motion.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Pain intensity
Time Frame: Baseline and at 6 weeks post-intervention
Pain intensity will be assessed using the Numeric Pain Rating Scale (NPRS). The scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores represent greater pain intensity.
Baseline and at 6 weeks post-intervention

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Grip strength
Time Frame: Baseline and at 6 weeks post-intervention
Grip strength will be measured using a hand dynamometer. Higher values indicate greater muscle strength.
Baseline and at 6 weeks post-intervention
Range of motion
Time Frame: Baseline and at 6 weeks post-intervention
Elbow and wrist range of motion will be measured using a standard goniometer. Higher values indicate improved joint mobility.
Baseline and at 6 weeks post-intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Green International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Prof Dr Fahad Tanveer, Green international University lahore

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 5, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 10, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 8, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 8, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 11, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 11, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 8, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • GIU/REC/26-41

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Due to patients privacy and confidentiality , IPD will not be shared

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Medial Epicondylitis

Clinical Trials on Dry needling

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings